The first vaccine against the Corona virus was authorized by the authorities in the European Union for use in all the countries that are part of the union, this after Great Britain, the USA, Canada, made similar decisions, and the vaccination processes have already begun.
The Romanian government is already preparing everything for the symbolic start of the vaccination process against the Coronavirus in Romania, 10.000 doses will arrive in our country in the following days, so that enough people will be able to be immunized as quickly as possible.
"Today, the European Commission granted a conditional marketing authorization (CMA) for the COVID-19 vaccine developed by BioNTech and Pfizer, making it the first COVID-19 vaccine authorized in the EU. This authorization follows a positive scientific recommendation based on a thorough evaluation of the safety, efficacy and quality of the vaccine by the European Medicines Agency (EMA) and is approved by the Member States.
European Commission President Ursula von der Leyen said: "Today we are adding an important chapter to a European success story. We have approved the first safe and effective vaccine against COVID-19. More vaccines are coming soon. The vaccine doses approved today will be available to all EU countries at the same time under the same conditions. The upcoming European Vaccination Days will also be a great moment of unity. This is a good way to end this difficult year and start turning the page on this pandemic. We are all in this together. "
Stella Kyriakides, Commissioner for Health and Food Safety, said: “This is a big day for Europe. It is a day of true European solidarity in action. After months of work, we are seeing our EU vaccine strategy pay off – access to safe, effective and affordable vaccines at the same time for all member states. Today we are witnessing what can be collectively achieved when we work together in a strong European Health Union. A Europe that cares and supports. A Europe that leaves no stone unturned. "
BioNTech and Pfizer submitted a formal application for a conditional marketing authorization on December 1. This followed analysis of their data in an "ongoing review" by the EMA from 6 October. Thanks to this continuous review, the EMA was able to assess the conditional marketing authorization application very quickly. This procedure, designed specifically for emergency situations, ensures the fastest possible assessment, while ensuring that all requirements for vaccine safety, efficacy and quality are fully and thoroughly assessed.”
